WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
PCSK9 inhibitors are an effective medication for lowering low-density lipoprotein levels, and their use has been associated with lower risk of poor cardiometabolic health. Some questions remain from trial data, however, relating to whether their use may have cognitive side-effects (e.g. memory). We used genetic variation in the PCSK9 gene to mimic use of these inhibitors in generally healthy middle-aged to older adults. We found limited evidence of association between the PCSK9 genetic risk score and worse cognitive scores; overall, pharmacovigilance is recommended.